This website is for UK Healthcare Professionals only

*Remission is based on CR, ORR and PR. CR is defined in the SmPC as complete remission.
UK-VNCCLL-220184 | May 2022

Video library

Haematology experts provide their opinions on key areas in the treatment of CLL patients

 

Clinical data for Venclyxto®(venetoclax) in CLL

MURANO 5-year update

Dr. Renata Walewska, Consultant Haematologist at the Royal Bournemouth Hospital, provides an overview of the 5-year update to the MURANO trial of venetoclax in combination with rituximab for relapsed/refractory CLL.

CLL-14 4-year update

Prof. Peter Hillmen, Consultant Haematologist at Leeds Teaching Hospitals NHS Trust provides an overview of the 4-year data from the CLL-14 clinical trial.

(9 mins)

(7 mins)


Expert Conversations in CLL clinical data and patient communication

Evolution of CLL therapy

George Follows, Consultant Haematologist and Cambridge University Hospitals NHS Foundation Trust, provides an overview of the evolution of therapy in CLL. 

Communicating risk and uncertainty  

Prof. Dame Lesley Fallowfield, Professor at Brighton and Sussex Medical School, and Director of the SHORE-C, discusses the lessons learnt in communication risk and uncertainty with patients during the COVID-19 pandemic.

(10 mins)

(22 mins)

Reviewing CLL patient cases

Dr. Talha Munir, Consultant Haematologist at St James’s Hospital, Leeds, discusses two complex CLL patient cases.

(27 mins)

CLL=Chronic lymphocytic leukaemia; CR=Complete remission; ORR=Overall response rate; PR=Partial response; SmPC=Summary of product characteristics.

References

  1. VENCLYXTO Summary of Product Characteristics.
  2. Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20.
  3. Fischer K et al. N Engl J Med. 2019; 380: 2225–36.

 

 

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to AbbVie on GBPV@abbvie.com

UK-VNCCLL-220194. Date of preparation: May 2022.